HIV resistance to lenacapavir weakens the virus's ability to replicate

Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with ...
eLife

HIV-specific CD8+ T-cell proliferative response 24 weeks after early antiretroviral therapy initiation is associated with the subsequent reduction in the viral reservoir

In individuals who started antiretroviral therapy during acute HIV infection, the proliferative capacity of HIV-specific CD8+ ...

Gilead Sciences, Inc.: European Medicines Agency Validates Gilead's Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for ...

One Application Seeks European Commission Authorization; Other Application Would Facilitate Availability in Low- and Lower-Middle-Income Countries - - Both Applications Will Be Assessed in Parallel ...
EuropaWire

Shionogi Increases Stake in ViiV Healthcare to 21.7 Percent as Shareholder Structure Simplifies

GSK and Shionogi have agreed with Pfizer to restructure ViiV Healthcare’s shareholder base, with Shionogi replacing Pfizer’s 11.7 percent economic interest and increasing its stake to 21.7 percent, ...
Irish Medical Times

You might be interested in…Infectious Disease and Vaccine Update

Dr Ray O’Connor takes a look at recent clinical articles on the importance of promoting vaccines for Measles, HIV, Gonorrhoea ...